The Cell Cycle: a Key to Unlock EZH2-targeted Therapy Resistance-Reference-Cited by-同舟云学术

The Cell Cycle: a Key to Unlock EZH2-targeted Therapy Resistance

Published:2024-06-03 Issue:6 Volume:14 Page:903-905
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:

Author:

Paolini Rachel L.¹²^ORCID,Souroullas George P.¹²³^ORCID

Affiliation:

1. 1Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri.

2. 2Division of Oncology, Molecular Oncology Section, Washington University School of Medicine in St. Louis, St. Louis, Missouri.

3. 3Siteman Comprehensive Cancer Center, Washington University School of Medicine in St. Louis, St. Louis, Missouri.

Abstract

Summary: In this issue, a study by Kazansky and colleagues explored resistance mechanisms after EZH2 inhibition in malignant rhabdoid tumors (MRT) and epithelioid sarcomas (ES). The study identified genetic alterations in EZH2 itself, along with alterations that converge on RB1-E2F–mediated cell-cycle control, and demonstrated that inhibition of cell-cycle kinases, such as Aurora Kinase B (AURKB) could bypass EZH2 inhibitor resistance to enhance treatment efficacy. See related article by Kazansky et al., p. 965 (6).

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/cancerdiscovery/article-pdf/14/6/903/3458431/903.pdf

Reference10 articles.

1. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer;Versteege;Nature,1998

2. Epigenetic antagonism between Polycomb and SWI/SNF complexes during oncogenic transformation;Wilson;Cancer Cell,2010

3. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2;Kim;Nat Med,2015

4. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2;Knutson;Proc Natl Acad Sci U S A,2013

5. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study;Gounder;Lancet Oncol,2020